Syfovre (pegcetacoplan)

Syfovre (pegcetacoplan) is covered only for geographic atrophy (GA) secondary to age‑related macular degeneration (non‑GA indications excluded) when the patient has documented GA, a BCVA of 24 letters or better on ETDRS charts, and the injection is administered by or under the supervision of an ophthalmologist. Approval is for 12 months with required documentation of the planned dose/interval (15 mg intravitreal to each affected eye every 25–60 days) and adherence to applicable safety and coverage criteria.

"Documentation of diagnosis: geographic atrophy secondary to age-related macular degeneration"

Sign up to see full coverage criteria, indications, and limitations.